AbbVie (ABBV) Competitors

$167.94
+1.53 (+0.92%)
(As of 04/22/2024 ET)

ABBV vs. MRK, JNJ, PFE, BMY, IQV, IDXX, MRNA, BNTX, ILMN, and JANX

Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Pfizer (PFE), Bristol-Myers Squibb (BMY), IQVIA (IQV), IDEXX Laboratories (IDXX), Moderna (MRNA), BioNTech (BNTX), Illumina (ILMN), and Janux Therapeutics (JANX). These companies are all part of the "medical" sector.

AbbVie vs.

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.3% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AbbVie has lower revenue, but higher earnings than Merck & Co., Inc.. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$60.12B5.35$365M$0.14906.71
AbbVie$54.32B5.47$4.86B$2.7361.52

AbbVie received 333 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 73.06% of users gave AbbVie an outperform vote while only 66.94% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
Merck & Co., Inc.Outperform Votes
966
66.94%
Underperform Votes
477
33.06%
AbbVieOutperform Votes
1299
73.06%
Underperform Votes
479
26.94%

In the previous week, AbbVie had 21 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 44 mentions for AbbVie and 23 mentions for Merck & Co., Inc.. AbbVie's average media sentiment score of 1.01 beat Merck & Co., Inc.'s score of 0.34 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merck & Co., Inc.
15 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
11 Very Positive mention(s)
4 Positive mention(s)
16 Neutral mention(s)
4 Negative mention(s)
3 Very Negative mention(s)
Neutral

Merck & Co., Inc. has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Merck & Co., Inc. currently has a consensus target price of $131.25, suggesting a potential upside of 3.40%. AbbVie has a consensus target price of $177.43, suggesting a potential upside of 5.65%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck & Co., Inc.
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58
AbbVie
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.77

Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.7%. Merck & Co., Inc. pays out 2,200.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 227.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 13 consecutive years and AbbVie has increased its dividend for 52 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AbbVie has a net margin of 8.95% compared to AbbVie's net margin of 0.61%. Merck & Co., Inc.'s return on equity of 162.28% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Merck & Co., Inc.0.61% 9.33% 3.61%
AbbVie 8.95%162.28%14.62%

Summary

AbbVie beats Merck & Co., Inc. on 17 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABBV vs. The Competition

MetricAbbViePharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$297.36B$6.42B$4.73B$17.40B
Dividend Yield3.73%3.11%5.49%3.59%
P/E Ratio61.5213.44239.6423.70
Price / Sales5.47297.652,567.9410.14
Price / Cash10.5219.0131.5414.84
Price / Book29.065.544.564.95
Net Income$4.86B$140.88M$101.37M$964.12M
7 Day Performance3.32%-2.18%-1.32%0.72%
1 Month Performance-5.89%-8.88%-6.66%-3.11%
1 Year Performance3.40%-0.15%8.28%94.37%

AbbVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRK
Merck & Co., Inc.
4.8242 of 5 stars
$125.06
-0.9%
$131.25
+4.9%
+10.0%$316.78B$60.12B893.2972,000Upcoming Earnings
Analyst Revision
Positive News
JNJ
Johnson & Johnson
4.8922 of 5 stars
$144.45
-2.1%
$177.31
+22.7%
-8.3%$348.09B$85.16B10.46131,900Earnings Report
Dividend Increase
Options Volume
PFE
Pfizer
4.9909 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-34.7%$145.47B$58.50B71.3688,000
BMY
Bristol-Myers Squibb
4.5629 of 5 stars
$48.27
-0.5%
$61.12
+26.6%
-30.3%$97.83B$45.01B12.5134,100Upcoming Earnings
IQV
IQVIA
4.8906 of 5 stars
$229.20
-0.8%
$256.80
+12.0%
+14.3%$41.60B$14.98B31.4487,000Positive News
IDXX
IDEXX Laboratories
4.1177 of 5 stars
$489.57
-0.4%
$591.50
+20.8%
-3.2%$40.66B$3.66B48.6211,000Positive News
MRNA
Moderna
3.9458 of 5 stars
$103.79
-0.1%
$126.49
+21.9%
-25.8%$39.74B$6.85B-8.365,600
BNTX
BioNTech
3.4881 of 5 stars
$86.34
-1.8%
$120.40
+39.4%
-25.6%$20.53B$4.13B20.966,133Analyst Revision
ILMN
Illumina
4.6466 of 5 stars
$117.69
-2.9%
$167.70
+42.5%
-47.2%$18.74B$4.50B-16.039,300
JANX
Janux Therapeutics
2.6261 of 5 stars
$50.55
-2.5%
$61.33
+21.3%
+217.2%$2.61B$8.08M-37.7264

Related Companies and Tools

This page (NYSE:ABBV) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners